Clinical trials: General Anxiety Disorder
Generalized Anxiety Disorder
A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder
This is a global, Phase 3, multicenter, open-label extension trial designed to evaluate the long-term safety, tolerability and efficacy of SEP-363856 administered at doses of 50 milligrams (mg) or 75 mg per day in adult…
- Trial name
- NCT07786454
- Testing
- SEP-363856
- Where
- 2 sites in United States
- Volunteers
- 1,120 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disease
A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects
The purpose of this study is to investigate if PD 0332334 affects the pharmacokinetics of lithium by co-administering both drugs to healthy adults.
- Trial name
- NCT00820794
- Testing
- Lithium, PD 0332334
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Anxiety Disorders
Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder
The investigators propose to develop and adapt Unwinding Anxiety phone app specifically for individuals with generalized anxiety disorder.
- Trial name
- NCT03683472
- Testing
- Unwinding Anxiety Phone App
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- MindSciences, Inc.
Generalized Anxiety Disorder
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD)
- Trial name
- NCT00236054
- Testing
- Gabitril
- Where
- 19 sites in United States
- Volunteers
- 440 people
- Sponsor
- Cephalon
Generalized Anxiety Disorder
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).
- Trial name
- NCT01844115
- Testing
- Vilazodone
- Where
- 36 sites in United States
- Volunteers
- 415 people
- Sponsor
- Forest Laboratories
Generalized Anxiety Disorder
Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of 2.5 mg and 10 mg vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
- Trial name
- NCT00731120
- Testing
- Vortioxetine
- Where
- 40 sites in United States
- Volunteers
- 457 people
- Sponsor
- Takeda
Anxiety Disorders
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in…
- Trial name
- AQUARIUS (NCT00266747)
- Testing
- SR58611A
- Where
- 7 sites in Argentina, Austria and 5 more
- Volunteers
- 366 people
- Sponsor
- Sanofi
General Anxiety Disorder
Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).
- Trial name
- NCT00233675
- Testing
- GABITRIL (tiagabine hydrochloride; CEP-6671)
- Where
- 28 sites in United States
- Sponsor
- Cephalon
Anxiety Disorder
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
To evaluate the efficacy of a fixed dose of SR58611A (350mg q12) compared to placebo in patients with GeneralizedAnxiety Disorder (GAD) using escitalopram (10 mg qd) as positive control.
- Trial name
- LIBRA (NCT00252343)
- Testing
- SR58611A
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).
The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo in the treatment of patients with general anxiety disorder (GAD).
- Trial name
- NCT00413010
- Testing
- pregabalin
- Where
- 68 sites in United States, Czechia and 6 more
- Volunteers
- 356 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.